Drugs / Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine
Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01744171 | Mar 2013 → Jun 2018 | cutaneous melanoma | Roswell Park Cancer Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01744171 ↗ |
| Modality | Vaccine | “Vaccine Therapy” NCT01744171 ↗ |
| Route | Other | “Patients receive recombinant hsp110-gp100 chaperone complex vaccine intradermally (ID)” NCT01744171 ↗ |